EMEA-001157-PIP01-11-M02
Key facts
| Active substance |
Caplacizumab
|
| Therapeutic area |
Haematology-Hemostaseology
|
| Decision number |
P/0294/2018
|
| PIP number |
EMEA-001157-PIP01-11-M02
|
| Pharmaceutical form(s) |
Powder and solvent for solution for injection
|
| Condition(s) / indication(s) |
Treatment of thrombotic thrombocytopenic purpura (TTP)
|
| Route(s) of administration |
|
| Contact for public enquiries |
Ablynx NV
E-mail: bernard.delaey@ablynx.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|
| Compliance procedure number |
EMEA-C-001157-PIP01-11-M02
|
| Compliance opinion date |
23/08/2019
|
| Compliance outcome |
positive
|